Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Comparing two therapies for alcohol addiction

Official title: Comparing the Efficacy of Combined Behavioral Intervention and Ericksonian Hypnotherapy in the Treatment of Alcohol Addiction: A Randomized Controlled Trial

Run by Beykoz University · NCT06916754 · Data updated 2026-11-12

This study is testing which therapy, Combined Behavioral Intervention or Ericksonian Hypnotherapy, works better to help adults with alcohol addiction reduce their drinking and improve their overall well-being.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment90 (estimated)
SponsorBeykoz University
Academic / other
Locations1 site (Istanbul)
StatusRecruiting
StartedMarch 1, 2025
Main results expectedNovember 15, 2025
Study endsFebruary 1, 2026
Registry record updatedApril 16, 2025
Trial IDNCT06916754 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 65 who meet the DSM-5 criteria for Alcohol Use Disorder and are medically stable.

Probably not a fit

Patients with severe psychiatric disorders, significant cognitive impairments, or those currently undergoing other structured addiction treatments may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study aims to compare the effectiveness of Combined Behavioral Intervention (CBI) and Ericksonian Hypnotherapy (EH) for individuals with Alcohol Use Disorder (AUD). The trial will include 90 adult participants who will be randomly assigned to one of the two treatment groups over a 12-week period. The study seeks to evaluate which therapy is more effective in reducing alcohol consumption and improving psychological well-being, while also assessing impacts on cravings, cognitive beliefs, and overall quality of life. By exploring these two distinct therapeutic approaches, the study hopes to identify the most suitable treatment for different individuals based on their unique needs.

Why it matters

Potential benefit: If successful, this study could provide a more effective treatment option for individuals struggling with alcohol addiction.

How similar studies have gone: While there is growing interest in hypnotherapy for addiction, this specific comparison of CBI and EH is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged between 18 and 65 years
* Meets DSM-5 diagnostic criteria for Alcohol Use Disorder (mild to severe)
* Medically and psychiatrically stable as determined by a clinician
* Willing and able to participate in weekly sessions over a 12-week period
* Provides informed consent

Exclusion Criteria:

* Current diagnosis of a severe psychiatric disorder (e.g., psychotic disorder, bipolar I disorder)
* Significant cognitive impairment that would interfere with treatment participation
* Participation in another structured addiction treatment during the study period
* Current use of psychotropic medications that may influence outcome measures (as assessed by the clinical team)
* Unstable medical condition requiring immediate intervention
* Pregnancy or planning to become pregnant during the study period

Where it's running

  • Beykoz University
    Istanbul, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.